Click here to get full coverage on Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing  Yahoo Finance

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance

Click here to get full coverage on Sirenia (CYBN) discloses 3,677,966 shares; 7.2% stake including warrants - Stock Titan

Sirenia (CYBN) discloses 3,677,966 shares; 7.2% stake including warrants  Stock Titan

Sirenia (CYBN) discloses 3,677,966 shares; 7.2% stake including warrants - Stock Titan

Click here to get full coverage on Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker - Sahm

Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker  Sahm

Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker - Sahm

Click here to get full coverage on Cybin alters state to become Helus Pharma for Nasdaq trip - Fierce Pharma

Cybin alters state to become Helus Pharma for Nasdaq trip  Fierce Pharma

Cybin alters state to become Helus Pharma for Nasdaq trip - Fierce Pharma

Click here to get full coverage on Cybin (CYBN) to Transfer Listing to Nasdaq in 2026 - GuruFocus

Cybin (CYBN) to Transfer Listing to Nasdaq in 2026  GuruFocus

Cybin (CYBN) to Transfer Listing to Nasdaq in 2026 - GuruFocus

Click here to get full coverage on Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - MSN

Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High?  MSN

Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - MSN

Click here to get full coverage on Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - Yahoo Finance

Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges  Yahoo Finance

Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on Point72 / Cohen disclose 686,669 shares in Cybin (CYBN) - Stock Titan

Point72 / Cohen disclose 686,669 shares in Cybin (CYBN)  Stock Titan

Point72 / Cohen disclose 686,669 shares in Cybin (CYBN) - Stock Titan

Click here to get full coverage on [SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan

[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure  Stock Titan

[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan

Click here to get full coverage on Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Yahoo Finance

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq  Yahoo Finance

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Yahoo Finance

Click here to get full coverage on Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan

Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief  Stock Titan

Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan

Click here to get full coverage on Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy - Yahoo Finance

Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy  Yahoo Finance

Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy - Yahoo Finance

Click here to get full coverage on Helus Pharma (Nasdaq: HELP) adds Langer and Brannan to scientific board - Stock Titan

Helus Pharma (Nasdaq: HELP) adds Langer and Brannan to scientific board  Stock Titan

Helus Pharma (Nasdaq: HELP) adds Langer and Brannan to scientific board - Stock Titan

Click here to get full coverage on New mental health drugmaker steps onto Nasdaq with two late-stage trials - Stock Titan

New mental health drugmaker steps onto Nasdaq with two late-stage trials  Stock Titan

New mental health drugmaker steps onto Nasdaq with two late-stage trials - Stock Titan

Click here to get full coverage on Millennium entities report 2.397M Cybin shares after >5% stake (CYBN) - Stock Titan

Millennium entities report 2.397M Cybin shares after >5% stake (CYBN)  Stock Titan

Millennium entities report 2.397M Cybin shares after >5% stake (CYBN) - Stock Titan

Click here to get full coverage on Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan

Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial  Stock Titan

Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan

Click here to get full coverage on Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan

Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push  Stock Titan

Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan

Click here to get full coverage on Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical - Stock Titan

Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical  Stock Titan

Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical - Stock Titan

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN - PR Newswire

Click here to get full coverage on Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan

Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel  Stock Titan

Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan

Click here to get full coverage on Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News - GuruFocus

Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News  GuruFocus

Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News - GuruFocus

Click here to get full coverage on Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus

Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq  GuruFocus

Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus

Click here to get full coverage on Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity Program - What's Changed - Sahm

Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity Program - What's Changed  Sahm

Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity Program - What's Changed - Sahm

Click here to get full coverage on Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat

Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says  MarketBeat

Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat

Click here to get full coverage on Cybin (CYBN) Initiates $100M At-the-Market Equity Program - GuruFocus

Cybin (CYBN) Initiates $100M At-the-Market Equity Program  GuruFocus

Cybin (CYBN) Initiates $100M At-the-Market Equity Program - GuruFocus

Click here to get full coverage on Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights  Business Wire

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire

Click here to get full coverage on Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN) - Seeking Alpha

Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN)  Seeking Alpha

Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN) - Seeking Alpha

Click here to get full coverage on Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025  Business Wire

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire

Click here to get full coverage on Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire

Cybin Initiates At-The-Market Equity Program of up to US$100 Million  Business Wire

Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire

Click here to get full coverage on Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha

Cybin Stock: Optimism Quickly Fades (NYSE:CYBN)  Seeking Alpha

Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha

Click here to get full coverage on Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel - GuruFocus

Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel  GuruFocus

Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel - GuruFocus

Click here to get full coverage on Cybin Announces $175 Million Registered Direct Offering - Business Wire

Cybin Announces $175 Million Registered Direct Offering  Business Wire

Cybin Announces $175 Million Registered Direct Offering - Business Wire

Click here to get full coverage on Cybin (CYBN) CEO Steps Down; Shares React - GuruFocus

Cybin (CYBN) CEO Steps Down; Shares React  GuruFocus

Cybin (CYBN) CEO Steps Down; Shares React - GuruFocus

Click here to get full coverage on Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones  Business Wire

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire

Click here to get full coverage on Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder  BioSpace

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace

Click here to get full coverage on Cybin Announces Senior Leadership Changes - Business Wire

Cybin Announces Senior Leadership Changes  Business Wire

Cybin Announces Senior Leadership Changes - Business Wire

Click here to get full coverage on Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Business Wire

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results  Business Wire

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Business Wire

Click here to get full coverage on Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures  Business Wire

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire

Click here to get full coverage on Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance

Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025  Yahoo Finance

Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance

Click here to get full coverage on Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development - Yahoo Finance

Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development  Yahoo Finance

Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development - Yahoo Finance

Click here to get full coverage on Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Yahoo Finance

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics  Yahoo Finance

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Yahoo Finance

Click here to get full coverage on Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Yahoo Finance

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Click here to get full coverage on Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - Stocktwits

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish  Stocktwits

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - Stocktwits

Click here to get full coverage on A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update - Stock Titan

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update  Stock Titan

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update - Stock Titan

Click here to get full coverage on Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround - Yahoo Finance

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround  Yahoo Finance

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Business Wire

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs  Business Wire

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Business Wire

Click here to get full coverage on CYBN Technical Analysis | Trend, Signals & Chart Patterns | CYBIN INC (NYSEARCA:CYBN) - ChartMill

CYBN Technical Analysis | Trend, Signals & Chart Patterns | CYBIN INC (NYSEARCA:CYBN)  ChartMill

CYBN Technical Analysis | Trend, Signals & Chart Patterns | CYBIN INC (NYSEARCA:CYBN) - ChartMill

Click here to get full coverage on Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003  Business Wire

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire

Click here to get full coverage on CYBN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

CYBN Stock: Price, Forecast, Financials & AI Analysis  Intellectia AI

CYBN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

Click here to get full coverage on CYBN Stock Price, News & Analysis - Stock Titan

CYBN Stock Price, News & Analysis  Stock Titan

CYBN Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - BioSpace

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025  BioSpace

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - BioSpace

Click here to get full coverage on Chicagoland Youth Basketball Network Opens Registration for May Tournaments - Scott Coop

Chicagoland Youth Basketball Network Opens Registration for May Tournaments  Scott Coop

Chicagoland Youth Basketball Network Opens Registration for May Tournaments - Scott Coop

Click here to get full coverage on Cybin (NYSE: CYBN) up 40% - not psychedelics, a hedge fund buying in - Dhaka Tribune

Cybin (NYSE: CYBN) up 40% - not psychedelics, a hedge fund buying in  Dhaka Tribune

Cybin (NYSE: CYBN) up 40% - not psychedelics, a hedge fund buying in - Dhaka Tribune

Click here to get full coverage on CYBN Forecast — Price Prediction for 2026. Should I Buy CYBN? - Intellectia AI

CYBN Forecast — Price Prediction for 2026. Should I Buy CYBN?  Intellectia AI

CYBN Forecast — Price Prediction for 2026. Should I Buy CYBN? - Intellectia AI

Click here to get full coverage on Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder - Business Wire

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder  Business Wire

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder - Business Wire

Click here to get full coverage on Cybin skyrockets as Steve Cohen’s hedge fund Point72 purchases almost 19M shares | NYSE-A:CYBN - Proactive financial news

Cybin skyrockets as Steve Cohen’s hedge fund Point72 purchases almost 19M shares | NYSE-A:CYBN  Proactive financial news

Cybin skyrockets as Steve Cohen’s hedge fund Point72 purchases almost 19M shares | NYSE-A:CYBN - Proactive financial news

Click here to get full coverage on Cybin (CYBN) Stock News & Updates - Stock Titan

Cybin (CYBN) Stock News & Updates  Stock Titan

Cybin (CYBN) Stock News & Updates - Stock Titan

Click here to get full coverage on Cybin Announces Conditional Listing Approval from NYSE American - Business Wire

Cybin Announces Conditional Listing Approval from NYSE American  Business Wire

Cybin Announces Conditional Listing Approval from NYSE American - Business Wire

Click here to get full coverage on Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - BioSpace

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose  BioSpace

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - BioSpace

Click here to get full coverage on 3 Best Psychedelic Stocks to Buy Now - InvestorPlace

3 Best Psychedelic Stocks to Buy Now  InvestorPlace

3 Best Psychedelic Stocks to Buy Now - InvestorPlace

Click here to get full coverage on HELP Stock Price and Chart — NEO:HELP - TradingView

HELP Stock Price and Chart — NEO:HELP  TradingView

HELP Stock Price and Chart — NEO:HELP - TradingView

Click here to get full coverage on Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far - Equity.Guru

Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far  Equity.Guru

Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far - Equity.Guru

Click here to get full coverage on Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules - Equity.Guru

Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules  Equity.Guru

Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules - Equity.Guru

Click here to get full coverage on Cybin Inc (AMEX: CYBN) - Share Price - intelligentinvestor.com.au

Cybin Inc (AMEX: CYBN) - Share Price  intelligentinvestor.com.au

Cybin Inc (AMEX: CYBN) - Share Price - intelligentinvestor.com.au

Click here to get full coverage on Cybin Inc. (CYBN) Share Price Today | Cybin (CYBN) Live NSE/BSE - Value Research

Cybin Inc. (CYBN) Share Price Today | Cybin (CYBN) Live NSE/BSE  Value Research

Cybin Inc. (CYBN) Share Price Today | Cybin (CYBN) Live NSE/BSE - Value Research

Click here to get full coverage on Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks

Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January  TipRanks

Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks

Click here to get full coverage on Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks

Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs  TipRanks

CYBN

Price Chart

Key Statistics

Technicals

About CYBN

Latest News

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance

Sirenia (CYBN) discloses 3,677,966 shares; 7.2% stake including warrants - Stock Titan

Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker - Sahm

Advanced Charts

Top Gainers

Top Losers